Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
BMJ Case Rep ; 13(10)2020 Oct 22.
Artigo em Inglês | MEDLINE | ID: mdl-33093060

RESUMO

Mucormycosis is an invasive mould that can cause aggressive infection, particularly in immunocompromised patients. Though oesophageal mucormycosis is relatively rare, it remains an elusive and devastating manifestation of this disease. The management is also challenging, due to surgical morbidity and contraindications such as thrombocytopenia in immunocompromised hosts. In this report, we present the case of a 60-year-old Lebanese man with newly diagnosed acute myeloid leukaemia who developed oesophageal mucormycosis after induction chemotherapy with idarubicin/cytarabine (7+3). The diagnosis was made when the patient developed febrile neutropenia and odynophagia. CT scan of the chest revealed a thickened oesophagus. Oesophagogastroduodenoscopy with biopsy, histopathology and PCR were performed, resulting in the diagnosis of Rhizopus microsporus The patient was successfully treated with liposomal amphotericin B and salvage posaconazole therapy without surgical intervention. We reviewed the clinical characteristics of the six published oesophageal mucormycosis reports from the literature.


Assuntos
Doenças do Esôfago/imunologia , Hospedeiro Imunocomprometido , Quimioterapia de Indução/efeitos adversos , Mucormicose/imunologia , Rhizopus/imunologia , Anfotericina B/uso terapêutico , Antifúngicos/uso terapêutico , Citarabina/efeitos adversos , Doenças do Esôfago/tratamento farmacológico , Doenças do Esôfago/parasitologia , Esôfago/imunologia , Esôfago/parasitologia , Humanos , Idarubicina/efeitos adversos , Leucemia Mieloide Aguda/tratamento farmacológico , Masculino , Pessoa de Meia-Idade , Mucormicose/tratamento farmacológico , Mucormicose/parasitologia , Triazóis/uso terapêutico
2.
BMJ Case Rep ; 13(2)2020 Feb 06.
Artigo em Inglês | MEDLINE | ID: mdl-32033999

RESUMO

Peritoneal tuberculosis (TB) is one of the most challenging forms of extrapulmonary tuberculosis to diagnose. This challenge can be compounded in low incidence regions, and in patients with cirrhosis in whom the presence of ascites alone may not prompt further investigation. A delay in the diagnosis and treatment of peritoneal tuberculosis may lead to worse clinical outcomes. This case describes a 64-year-old Italian male with decompensated cirrhosis being evaluated for liver transplantation, who developed abdominal pain and a persistent inflammatory ascites with peritoneal thickening despite antibiotic therapy. Peritoneal tuberculosis was suspected, although non-invasive and invasive direct mycobacterial testing remained negative. A constellation of positive QuantiFERON-TB Gold In-Tube test, elevated ascitic adenosine deaminase and dramatic symptomatic and radiographic response to empiric anti-tuberculous therapy confirmed the diagnosis of peritoneal tuberculosis. This paper will review the approach to the diagnosis of peritoneal tuberculosis.


Assuntos
Dor Abdominal/etiologia , Ascite/etiologia , Peritonite Tuberculosa/diagnóstico , Diagnóstico Diferencial , Testes Hematológicos , Humanos , Masculino , Pessoa de Meia-Idade , Peritônio , Tomografia por Emissão de Pósitrons
3.
BMJ Case Rep ; 20162016 Nov 16.
Artigo em Inglês | MEDLINE | ID: mdl-27852682

RESUMO

Mycobacterium tuberculosis presents unique challenges in the peritransplant period. Here, we describe a case of disseminated tuberculosis following renal transplantation with alemtuzumab induction immunosuppression in a patient with remotely treated pulmonary tuberculosis and ongoing risk factors for re-infection. We also review the available literature regarding the prevalence of tuberculosis infection following solid organ transplant and management of high-risk patients, including the role for isoniazid preventative therapy.


Assuntos
Anticorpos Monoclonais Humanizados/efeitos adversos , Terapia de Imunossupressão/efeitos adversos , Isoniazida/uso terapêutico , Transplante de Rim/efeitos adversos , Mycobacterium tuberculosis , Infecções Oportunistas/microbiologia , Tuberculose/etiologia , Idoso , Alemtuzumab , Antituberculosos/uso terapêutico , Feminino , Humanos , Imunossupressores/efeitos adversos , Infecções Oportunistas/etiologia , Infecções Oportunistas/prevenção & controle , Tuberculose/microbiologia , Tuberculose/prevenção & controle , Tuberculose Miliar/etiologia , Tuberculose Miliar/microbiologia , Tuberculose Miliar/prevenção & controle , Tuberculose Pulmonar/tratamento farmacológico , Tuberculose Pulmonar/microbiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA